Previous close | 22.86 |
Open | 22.54 |
Bid | 21.84 x 400 |
Ask | 21.91 x 400 |
Day's range | 21.81 - 22.61 |
52-week range | 14.89 - 32.53 |
Volume | |
Avg. volume | 635,820 |
Market cap | 1.984B |
Beta (5Y monthly) | 1.07 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.85 |
Earnings date | 08 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 50.08 |
Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
CRANBURY, N.J., May 29, 2024--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the European Commission (EC), based on a positive opinion issued by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), has granted orphan medicinal product designation for RP-A601, the Company’s adeno-associated viru